Search Results - "Sartor, A. O."

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial by Bahl, A., Oudard, S., Tombal, B., Özgüroĝlu, M., Hansen, S., Kocak, I., Gravis, G., Devin, J., Shen, L., de Bono, J.S., Sartor, A.O.

“…Cabazitaxel significantly improves overall survival (OS) versus mitoxantrone in patients with metastatic castration-resistant prostate cancer after docetaxel…”
Get full text

On the actions of the growth hormone-releasing hexapeptide, GHRP by Bowers, C Y, Sartor, A O, Reynolds, G A, Badger, T M

“…GH-releasing peptide (His-DTrp-Ala-Trp-DPhe-Lys-NH2 or GHRP) releases GH by a unique and complementary dual site of action on the hypothalamus and pituitary…”
Get more information

A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer by THIBAULT, A, COOPER, M. R, MYERS, C. E, FIGG, W. D, VENZON, D. J, SARTOR, A. O, TOMPKINS, A. C, WEINBERGER, M. S, HEADLEE, D. J, MCCALL, N. A, SAMID, D

“…Phenylacetate has recently been shown to suppress tumor growth and promote differentiation in experimental models. A phase I trial of phenylacetate was…”
Get full text

Myeloperoxidase: An Enzyme Involved in Intrinsic Vincristine Resistance in Human Myeloblastic Leukemia by Schlaifer, Daniel, Cooper, Michael R., Attal, Michel, Sartor, A. Oliver, Trepel, Jane B., Laurent, Guy, Myers, Charles E.

“…One of the differences between acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL) is their sensitivity to vincristine. Although…”
Get full text

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study ( SWOG 9235) by Kucuk, Omer, Fisher, Emily, Moinpour, Carol M, Coleman, Dorothy, Hussain, Maha H.A, Sartor, A.Oliver, Chatta, Gurkamal S, Lowe, Bruce A, Eisenberger, Mario A, Crawford, E.David

“…Objectives. To determine the efficacy and tolerability of bicalutamide in patients with advanced prostate cancer with progression after conventional hormonal…”
Get full text

Anaphylactoid reaction with suramin by Thibault, A, Figg, W D, Cooper, M R, Prindiville, S A, Sartor, A O, Headlee, D J, Myers, C E

“…Suramin, a drug used to treat parasitic diseases, is currently being investigated as a treatment for metastatic prostate cancer. A 73-year-old man had an…”
Get more information

Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Estimating mean overall survival (OS) for health economic analyses from a phase III trial (TROPIC) by Oudard, S., Joulain, F., De Geer, A., Sartor, A. O.

“…Abstract only 128^ Background: TROPIC evaluated the efficacy and safety of the novel taxane cabazitaxel in men with mCRPC previously treated with docetaxel…”
Get full text

Educating African American men on prostate health and informed decision making: Initial report from a peer-education program in Louisiana by Robinson, M. M., Sartor, A. O., Jack, L.

“…Abstract only 211 Background: Informed decision making for prostate cancer health is widely endorsed but systematic programs to address this need are sparse…”
Get full text

Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease by Bennett, Charles L., Qureshi, Zaina P., Sartor, A. Oliver, Norris, LeAnn B., Murday, Alanna, Xirasagar, Sudha, Thomsen, Henrik S.

“…Background.In 2006, nephrologists in Denmark unexpectedly identified chronic kidney disease (CKD) patients with a new syndrome, nephrogenic systemic fibrosis…”
Get full text

Interactions of cytokine gene polymorphisms in prostate cancer risk by Zabaleta, Jovanny, Lin, Hui-Yi, Sierra, Rosa A., Hall, M.Craig, Clark, Peter E., Sartor, Oliver A., Hu, Jennifer J., Ochoa, Augusto C.

“…Prostate cancer (CaP) is the second leading cause of cancer death in American men. Chronic inflammation has been one of several factors associated with the…”
Get full text

Cytokine genetic polymorphisms and prostate cancer aggressiveness by Zabaleta, Jovanny, Su, L. Joseph, Lin, Hui-Yi, Sierra, Rosa A., Hall, M. Craig, Sartor, A. Oliver, Clark, Peter E., Hu, Jennifer J., Ochoa, Augusto C.

“…Prostate cancer (PCa) is one of the most common cancers in the world. Inflammation has been described as a risk factor for PCa and depends on the production of…”
Get full text

Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial by Sartor, A. O., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. H., Shen, L., De Bono, J. S.

“…Abstract only…”
Get full text

Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel by Ozguroglu, M., Oudard, S., Sartor, A. O., Hansen, S., Machiels, J. H., Shen, L., De Bono, J. S.

“…Abstract only…”
Get full text

A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) by De Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. H., Shen, L., Sartor, A. O.

“…Abstract only…”
Get full text

Effect of G-CSF prophylaxis on the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study by Ozguroglu, M., Oudard, S., Sartor, A. O., Hansen, S., Machiels, J. H., Shen, L., De Bono, J. S.

“…Abstract only 144^ Background: The phase III TROPIC study showed that cabazitaxel plus prednisone (CbzP) improves survival compared with mitoxantrone plus…”
Get full text

Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC) by De Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. H., Shen, L., Matthews, P., Sartor, A. O.

“…Abstract only…”
Get full text

Factors associated with a delay in diagnosis of recurrent prostate cancer after radical prostatectomy by Hoffman, K. E., Chen, M., Nguyen, P. L., Bennett, C. L., Sartor, A. O., Stein, K., Kuban, D. A., D'Amico, A. V.

“…Abstract only 208 Background: Salvage radiation therapy has an improved chance of increasing prostate cancer survival if it is administered at the earliest…”
Get full text

Comorbidity and treatment regret in men with recurrent prostate cancer by Nguyen, P. L., Chen, M., Chen, R. C., Hoffman, K. E., Hu, J. C., Bennett, C. L., Kattan, M. W., Sartor, A. O., Stein, K., D'Amico, A. V.

“…Abstract only 187 Background: To determine whether concurrent comorbidity is associated with treatment regret among men with PSA recurrence following primary…”
Get full text

A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902 by Sandler, H. M., Hunt, D., Sartor, A. O., Gomella, L. G., Hartford, A., Zeitzer, K. L., Rajan, R., Kerlin, K., Michalski, J. M., Rosenthal, S. A.

“…Abstract only…”
Get full text

Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial by Sartor, A. O., Petrylak, D., Sternberg, C., Witjes, F., Halabi, S., Berry, W., Petrone, M., McKearn, T., Noursalehi, M., George, M.

“…Abstract only 5148 Background: First-line chemotherapy trials have reported that pain predicts OS in CRPC. We report relationships between OS and baseline pain…”
Get full text